false
0001500198
0001500198
2026-02-25
2026-02-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 25, 2026
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40439 |
|
27-0863354 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip
code)
952-426-1383
(Registrant’s telephone number including
area code)
(Registrant’s former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
NMTC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Items.
The Board of Directors of NeuroOne Medical Technologies
Corporation (the “Company”) has established April 3, 2026 as the date of the Company’s 2026 annual meeting of stockholders
(the “2026 Annual Meeting”). The Company plans to publish additional details regarding the exact time, location and matters
to be voted on at the 2026 Annual Meeting in the Company’s proxy statement for the 2026 Annual Meeting.
Because the date of the 2026 Annual Meeting will
change by more than 30 calendar days from the anniversary date of the Company’s 2025 annual meeting of stockholders, the Company
has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934,
as amended (“Rule 14a-8”) for inclusion in the Company’s proxy materials relating to the 2026 Annual Meeting. In order
for a proposal under Rule 14a-8 to be timely, it must be received by the Company’s Secretary at the principal executive offices
of the Company by March 4, 2026, which the Company has determined to be a reasonable time before the Company’s proxy materials are
due to be printed and sent.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
NEUROONE MEDICAL TECHNOLOGIES CORPORATION |
| Dated: February 25, 2026 |
|
|
| |
By: |
/s/ David Rosa |
| |
|
David Rosa |
| |
|
Chief Executive Officer |
2
